Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

BioXcel Therapeutics (BTAI) Return on Capital Employed (2022 - 2025)

Historic Return on Capital Employed for BioXcel Therapeutics (BTAI) over the last 4 years, with Q3 2025 value amounting to 20.16%.

  • BioXcel Therapeutics' Return on Capital Employed rose 225800.0% to 20.16% in Q3 2025 from the same period last year, while for Sep 2025 it was 20.16%, marking a year-over-year increase of 225800.0%. This contributed to the annual value of 1.99% for FY2024, which is 4600.0% down from last year.
  • As of Q3 2025, BioXcel Therapeutics' Return on Capital Employed stood at 20.16%, which was up 225800.0% from 43.17% recorded in Q2 2025.
  • BioXcel Therapeutics' Return on Capital Employed's 5-year high stood at 43.17% during Q2 2025, with a 5-year trough of 4.12% in Q1 2025.
  • Moreover, its 4-year median value for Return on Capital Employed was 2.39% (2024), whereas its average is 3.27%.
  • Per our database at Business Quant, BioXcel Therapeutics' Return on Capital Employed crashed by -20400bps in 2023 and then soared by 455200bps in 2025.
  • Quarter analysis of 4 years shows BioXcel Therapeutics' Return on Capital Employed stood at 0.83% in 2022, then plummeted by -246bps to 2.87% in 2023, then dropped by -9bps to 3.14% in 2024, then skyrocketed by 741bps to 20.16% in 2025.
  • Its last three reported values are 20.16% in Q3 2025, 43.17% for Q2 2025, and 4.12% during Q1 2025.